诊断市场研究回顾：2024 年

全球临床和分子诊断 AI 市场规模预计将从 2024 年的 年终的 89 亿美元，预测期内的复合年增长率为 27.6%。

全球伴同性诊断市场规模预计将从 2023 年的 76 亿美元增加到 2028 年的 154 亿美元，预测期间的复合年增长率为 15.2%。

全球血液学治疗和诊断市场规模预计将从 2024 年的 年终的 1,893 亿美元，预测期内的复合年增长率为 7.6%。

儘管近年来经济状况严峻，但诊断产业仍蓬勃发展。该行业一直是公众和政府关注和审查的对象，由于监管重点的加强，目前正在发生许多变化。许多国家都出现了这些变化。作为最大的诊断市场，美国正以降低医疗费用为目标转型，引领这一趋势。诊断产业的机会是多方面的，这主要归功于新兴国家中出现了具有不同需求的新兴市场。

医疗成本的上升和新兴经济体的成长推动了对技术更先进的诊断设备、套件、试剂和其他配件的需求。此外，已开发市场（特别是美国和欧洲）推出了更严格的监管规定，迫使诊断製造商推出包含新材料、更深的指征重点和产生更多新资料的能力的先进产品。

推动市场发展的关键因素是慢性病和感染疾病的增加、诊断技术的进步、诊断市场对人工智慧的投资增加、非肿瘤学应用数量的增加以及对个人化医疗的兴趣日益浓厚。

本研究评论包括BCC Research于2024年发布的有关临床和分子诊断AI、伴同性诊断技术、血液病治疗和诊断、体外诊断（IVD）品管、POC技术、POC诊断的PCR以及罕见病诊断技术的报告的亮点和摘录，并包括全面的市场概览、市场影响因素和市场机会的分析、法律制度的详细趋势

目录

第 1 章 简介

2. 临床和分子诊断市场中的人工智慧（BIO261A）

• 临床和分子诊断中的人工智慧
• 市场展望
• 研究范围
• 市场摘要
• 市场概况
• 医疗保健领域的人工智慧
• 临床诊断中的人工智慧
• 分子诊断中的人工智慧
• 市场动态
• 市场驱动因素
• 投资AI医疗领域
• 慢性病和感染疾病增多
• 技术进步
• 个性化医疗的需求
• 市场限制
• 从业者不愿意采用基于人工智慧的技术
• 资料安全
• 监管挑战
• 市场机会
• 人工智慧软体
• 新兴市场中尚未开发的机会
• 法律规范
• 新兴技术和发展
• 机器学习演算法
• 深度学习
• 生成式人工智慧
• 自然语言处理 (NLP)
• 基因组人工智慧
• 云端基础的解决方案
• 市场区隔分析
• 临床和分子诊断中的人工智慧：全球市场
• 分子诊断
• 临床诊断
• 零件市场分析
• 软体
• 服务
• 硬体
• 地理分布
• 市场分析：按地区
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

第 3 章伴同性诊断：技术与市场（BIO077F）

• 伴同性诊断
• 市场展望
• 研究范围
• 市场摘要
• 伴同性诊断 (CDx) 市场亮点
• 市场概况
• 监管状态
• 美国伴同性诊断法规
• 美国以外地区的伴同性诊断监管
• LDT-CDx 法规
• 市场动态
• 市场驱动因素
• 癌症发生率增加
• 扩大个人化医疗的引入
• 扩大应用范围至非肿瘤领域
• 优化药物开发成本
• 市场限制
• CDx 开发成本高
• 报销挑战
• 市场机会
• NGS 技术的进展
• 市场挑战
• 临床试验效率低下
• 技术纯熟劳工短缺
• 新兴技术和发展
• 多重测试
• 次世代定序（NGS）
• 数位 PCR
• 液态生物检体
• AI
• 市场区隔分析
• 全球伴同性诊断市场（按产品和服务）
• 市场占有率和预测
• 装置
• 耗材
• 服务
• 全球伴同性诊断市场（按测试类型）
• 市场占有率和预测
• LDT-CDx
• 商业化伴随诊断
• 全球伴同性诊断市场（按技术）
• 市场占有率和预测
• PCR
• 免疫组织化学
• 次世代定序
• 原位杂交
• 基因型鉴定
• 免疫检测
• 外泌体
• 其他的
• 服务
• 全球伴同性诊断市场（按应用）
• 市场占有率和预测
• 癌症
• 全球伴同性诊断市场类型
• 神经系统疾病
• 心血管疾病
• 感染疾病
• 其他的
• 全球伴同性诊断市场（按最终用户划分）
• 市场占有率和预测
• 临床实验室
• 製药公司
• CRO
• 其他的
• 地理分布
• 全球伴同性诊断市场（按区域）
• 北美洲
• 美国
• 加拿大
• 欧洲
• 德国
• 英国
• 法国
• 义大利
• 其他的
• 亚太地区
• 中国
• 日本
• 印度
• 其他的
• 其他地区

4. 血液学药物与诊断：全球市场 (PHM116C)

• 血液疾病药物和诊断
• 市场展望
• 研究范围
• 市场摘要
• 市场概况
• PESTEL 分析
• 波特五力分析
• 供应炼和物流
• 市场动态
• 市场驱动因素
• 血液疾病发生率
• 增加自动化使用
• 血液疾病的诊断
• 增加政府和私人治疗资金
• 市场限制
• 设备高成本
• 医疗费用上涨
• 医生报销问题
• 市场机会
• 增强健康意识
• 新兴经济体
• 新兴技术和发展
• 人工智慧辅助诊断
• 次世代定序（NGS）
• 微流体和实验室晶片设备
• 基因治疗
• 免疫疗法
• 市场区隔分析
• 市场区隔
• 血液疾病诊断市场
• 血液学诊断市场（依产品类型）
• 血液学诊断市场（按最终用户划分）
• 血液学药物市场
• 血液学药物市场（按药物类型）
• 地理分布
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

5. 体外诊断（IVD）品管：全球市场（BIO233B）

• 体外诊断（IVD）品管
• 市场展望
• 研究范围
• 市场摘要
• 市场及技术背景
• 概述
• 体外诊断药品分类
• IVD品管的重要性
• 规则
• 各国IVD产品监管
• IVD品管：市场动态
• 市场驱动因素
• 人口老化加剧，对频繁诊断程序的依赖
• 对第三方品管产品的需求不断增加
• 慢性病发生率上升
• 加强临床实验室
• 提高 POC 测试的品质
• 市场限制
• 品管产品包装挑战
• 运输成本增加和服务问题
• 实验室设备和耗材操作和维护不当
• 市场机会
• 居家照护检测设备增加
• POC 测试单元的需求
• 新兴技术和发展
• AI
• 优先考虑较老的 IVD 技术
• IVD设备自动化
• IVD 的新兴趋势
• FDA核准
• 个人化医疗需求日益增长
• 市场区隔分析
• 市场区隔：按测试类型
• 免疫诊断
• 临床化学
• 血液学
• 分子诊断
• 微生物
• 其他的
• 市场区隔：按製造商
• 第三方控制
• ODM控制
• IVD品管产品与服务市场细分
• 品管产品
• 资料管理解决方案
• 品质保证服务
• 市场区隔：按最终用户
• 诊断实验室
• 医院和诊所
• 点检中心
• 研究所
• 其他的
• 地理分布
• 市场区隔：按地区
• 北美洲
• 市场规模及预测
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 市场规模及预测
• 德国
• 法国
• 英国
• 义大利
• 西班牙
• 其他欧洲国家
• 亚太地区
• 市场规模及预测
• 日本
• 中国
• 印度
• 澳洲和纽西兰
• 其他的
• 其他地区
• 市场规模及预测
• 巴西
• 海湾合作委员会国家
• 其他地区

6. POC 诊断：技术与全球市场（HLC043H）

• POC 诊断
• 市场展望
• 研究范围
• 市场摘要
• POC 诊断：市场概览
• POC 的新方法
• CLIA 在美国的重要性
• 监管指南
• 良好生产规范
• FDA 在 POC 研究中的作用
• 结论
• POC 诊断：市场动态
• 市场驱动因素
• 感染疾病率高
• 慢性病增加
• 自我检测需求不断成长
• 高龄化社会
• 市场限制
• 定价压力挑战 POC 製造商
• 技术复杂性
• 缺乏专业培训
• 市场挑战
• 在偏远地区引入 POC 诊断的挑战
• POC 诊断中的环境与污染挑战
• 市场机会
• 增加研发预算
• AI与ML的融合为POCT带来巨大市场潜力
• 新兴经济体
• 市场上的新兴和未来技术
• POC 诊断中的 AI
• CRISPR-Cas系统
• 3D快速原型製作
• 量子点
• RFID 和 NFC
• 基于智慧型手机的医学影像
• 用于病原体检测的 POC 设备中的奈米材料
• 基于微流体的感测技术
• 云端整合人工智慧
• D3 阵列-UTI
• EVIK DxSpheres：强大的检测解决方案
• UNIQO 160 自动 IIFT 系统
  • 最新动态
• 市场区隔分析
• 市场区隔：按测试类型
• 药物和酒精测试
• 血气电解质和代谢物 (BGEM)
• 心臟标记物
• 胆固醇检测/监测
• 检测和监测血糖值
• 传染病检查
• 妊娠和生育测试
• 血红素与止血
• 肿瘤标记
• 尿液检查/尿液化学
• 其他的
• 市场区隔：按产品
• 硬体
• 软体
• 市场区隔：按最终用户
• 医院及加护病房
• 居家照护
• 地理分布
• 市场区隔：按地区
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

第 7 章 POC 诊断的 PCR（BIO157C）

• PCR 用于 POC 诊断
• 市场展望
• 研究范围
• 市场摘要
• 市场概况
• PCR 技术
• POC PCR 系统与检测
• 市场动态
• 市场驱动因素
• 感染疾病率上升
• 分散式测试
• POC 测试的引入与扩展
• 多路復用测试
• 应对疫情
• 市场机会
• PCR POC 技术在基层医疗和低收入国家的整合
• 市场限制
• 初期成本高
• 市场竞争
• 市场挑战
• 营运挑战
• 供不应求
• 新兴技术和发展
• 无需设备的 PCR 检测
• 5 分钟 POC 测试
• 相容智慧型手机的 PCR 系统
• PCR POC 诊断的全球市场
• 按产品类型分類的市场
• 市场区隔：依分析对象
• PCR POC 分析仪
• PCR POC 耗材
• 市场区隔：按应用
• 感染疾病
• 性行为感染传染病
• 地理分布
• 市场区隔：按地区
• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 其他地区

8. 罕见疾病诊断：技术与全球市场（PHM227B）

• 罕见疾病诊断
• 市场展望
• 研究范围
• 市场摘要
• 市场概况
• 诊断奥德赛
• 什么是基因组测试？
• 罕见疾病临床试验的开发与行销
• 治疗罕见疾病
• 罕见疾病研究和遗传学的生物资讯学资源
• 大型倡议和联盟
• 大规模定序计划
• 市场动态
• 市场驱动因素
• 罕见疾病诊断领域仍存在大量未满足的需求
• 孤儿药法案
• 基因治疗的进展
• 罕见疾病因应倡议
• 基因组技术和分析工具的进展
• 降低NGS成本
• 市场驱动力及其对市场成长的影响
• 市场限制
• 缺乏可用于罕见疾病诊断的商用 IVD 诊断设备
• 监理环境严峻
• 道德和法律问题
• 遗传和罕见疾病专家短缺
• 新兴技术和发展
• 迈向多体学方法
• 人工智慧和机器学习
• 罕见疾病诊断及药厂合作
• 市场区隔分析
• 按分析平台分類的市场
• NGS
• PCR
• 桑格定序
• 微阵列
• 核型分析和萤光杂合反应(FISH)
• 生物化学检验
• 市场区隔：依分析类型
• 单基因
• 多基因
• 全EXOME
• 全基因组
• 其他基因突变
• 蛋白质和其他生化标记
• 市场区隔：依疾病类别
• 罕见癌症
• 神经系统疾病
• 代谢和内分泌失调
• 血液学
• 呼吸系统
• 免疫系统与发炎相关疾病
• 皮肤
• 肌肉骨骼
• 其他的
• 市场区隔：依测试目的
• 诊断
• 筛检和早期检测
• 治疗指导
• 监控
• 地理分布
• 市场区隔：按地区
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

第 9 章 附录

The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.

The global market for companion diagnostics is estimated to increase from $7.6 billion in 2023 and is projected to reach $15.4 billion by 2028, at a CAGR of 15.2% from 2023 through 2028.

The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a CAGR of 7.6% during the forecast period of 2024 to 2029.

Research Review Scope

The diagnostics industry has grown despite the challenging economic conditions in recent years. The industry draws much attention and scrutiny from the public and government and is currently undergoing many changes due to increased focus on regulations. These changes can be seen across many countries. The U.S., the largest diagnostics market, is leading the trend with changes intended to make healthcare more affordable. Opportunities for the diagnostics industry are manifold with the appearance of new markets located mainly in emerging economies with varying needs.

Increasing healthcare expenditures and the growth of emerging economies have increased the demand for technologically better diagnostic devices, kits, reagents, and other accessories. Additionally, the introduction of more stringent regulations, specifically in the developed markets of the U.S. and Europe, has forced diagnostics manufacturers to launch advanced products that include new materials, a focus on in-depth indications, and the ability to produce additional new data.

Some of the major driving factors in the market are increasing prevelance of chronic and infectious diseases, technological advancements in the diagnostics, increasing investments in AI in diagnostics market, increased applications in non-oncology areas, growing adotion of personalized medicine, and other driving factors.

Furthermore, technically sophisticated diagnostics are needed for clinical research, as the market is highly competitive, and companies must continuously reinvent their product portfolios to enter new markets and place themselves as significant players in the healthcare system. There is a shift toward a value-based healthcare market where price and purchase decisions are based on outcomes. This has further resulted in increased scrutiny of the technology of devices, and consequently, the degree of competition has risen. Some of the major players in the diagnostics market include Abbott, Medtronic, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, GE Healthcare, Koninklijke Philips N.V., Agilent Technologies Inc., QIAGEN, Danaher Corp., Sysmex, Thermo Fisher Scientific, Inc., BD, and others.

The diagnostics industry is a multi-billion-dollar market whose outlook is supposed to rise in the coming years. Hospital care is growing, and the diagnostics industry is being looked at to provide low-cost technology for home healthcare. Now, the industry seeks healthcare diagnostic devices, kits, and reagents that individuals with unskilled healthcare experience can use. The need for modern technology, equipment, and devices can be leveraged through diagnostic equipment as manufacturers seek to create better-quality healthcare solutions.

Today's market is worthy of close investigation as it deals with the fallout from COVID-19 and how the global diagnostics market is after the post-COVID-19 pandemic. The global pandemic has impacted the diagnostics industry both positively and negatively.

The above reasons are compelling enough to analyze and research the diagnostics market, as the market has tremendous growth potential.

It includes highlights from these reports published in 2024:

• BIO261A AI in Clinical and Molecular Diagnostics Market
• BIO077F Companion Diagnostics: Technologies and Global Markets
• PHM116C Drugs and Diagnostics for Hematological Disorders Global Markets
• BIO233B In Vitro Diagnostics (IVD) Quality Controls: Global Market
• HLC043H Point of Care Diagnostics: Technologies and Global Markets
• BIO157C Polymerase Chain Reaction (PCR) for Point of Care (POC) Diagnostics
• PHM227B Rare Disease Diagnostics: Technologies and Global Markets

After you survey the excerpts in this Research Review, we encourage you to follow up on these topics by checking out the full market research reports associated with each topic. BCC Research looks forward to serving your market intelligence needs in the future.

Table of Contents

Chapter 1 Foreword

• Research Review Scope

Chapter 2 AI in Clinical and Molecular Diagnostics Market(BIO261A)

• AI in Clinical and Molecular Diagnostics
• Market Outlook
• Scope of Report
• Market Summary
• Market Overview of AI in Clinical and Molecular Diagnostics
• AI in Healthcare
• AI in Clinical Diagnostics
• AI in Molecular Diagnostics
• Market Dynamics of AI in Clinical and Molecular Diagnostics
• Market Drivers
• Investment in the AI Health Sector
• Increasing Prevalence of Chronic and Infectious Diseases
• Technological Advances
• Demand for Personalized Medicine
• Market Restraints
• Practitioners Reluctant to Adopt AI-based Technologies
• Data Security
• Regulatory Challenges
• Market Opportunities
• Software with AI
• Untapped Opportunities in Developing Markets
• Regulatory Structure
• Emerging Technologies and Developments
• Machine Learning Algorithms
• Deep Learning
• Generative AI
• Natural Language Processing (NLP)
• Genomic AI
• Cloud-Based Solutions
• Market Segmentation Analysis
• AI in Clinical and Molecular Diagnostics: Global Markets
• Molecular Diagnostics
• Clinical Diagnostics
• Market Analysis of AI in Clinical and Molecular Diagnostics by Component
• Software
• Services
• Hardware
• Geographic Breakdown
• Market Analysis 0f AI in Clinical and Molecular Diagnostics by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 3 Companion Diagnostics: Technologies and Markets ( BIO077F)

• Companion Diagnostics
• Market Outlook
• Scope of Report
• Market Summary
• Highlights of the Market for Companion Diagnostics (CDx)
• Market Introduction
• Regulatory Landscape
• Companion Diagnostics Regulations in the U.S.
• Companion Diagnostics Regulations Outside the U.S.
• LDT-CDx Regulation
• Market Dynamics of Companion Diagnostics
• Market Drivers
• Rising Incidence of Cancer
• Growing Adoption of Personalized Medicine
• Expanded Application in Non-Oncology Areas
• Optimization of Drug Development Costs
• Market Restraints
• High Development Cost of CDx
• Reimbursement Challenges
• Market Opportunities
• Advances in NGS Technologies
• Market Challenges
• Inefficiencies in Clinical Testing Landscape
• Lack of Skilled Labor
• Emerging Technologies and Developments
• Multiplex Testing
• Next-Generation Sequencing (NGS)
• Digital PCR
• Liquid Biopsy
• Artificial Intelligence
• Market Segmentation Analysis
• Global Market for Companion Diagnostics by Product and Service
• Market Share and Forecast
• Instruments
• Consumables
• Services
• Global Market for Companion Diagnostics by Type of Test
• Market Share and Forecast
• LDT-CDx
• Commercial CDx
• Global Market for Companion Diagnostics by Technology
• Market Share and Forecast
• Polymerase Chain Reaction
• Immunohistochemistry
• Next-Generation Sequencing
• In Situ Hybridization
• Genotyping
• Immunoassays
• Exosomes
• Others
• Services
• Global Market for Companion Diagnostics by Application
• Market Share and Forecast
• Cancer
• Market for the Application of CDx in Cancer by Type
• Neurologic Disorders
• Cardiovascular Disease
• Infectious Diseases
• Other Diseases
• Market Breakdown of Companion Diagnostics by End User
• Market Share and Forecast
• Clinical Laboratories
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Other End Users
• Geographic Breakdown
• Global Market for Companion Diagnostics by Region
• North America
• The U.S.
• Canada
• Europe
• Germany
• The U.K.
• France
• Italy
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
• Rest of the World

Chapter 4 Drugs and Diagnostics for Hematological Disorders: Global Markets (PHM116C)

• Drugs and Diagnostics for Hematological Disorders
• Market Outlook
• Scope of Report
• Market Summary
• Market Overview of Drugs and Diagnostics for Hematological Disorders
• PESTEL Analysis
• Political
• Economic
• Social
• Technological
• Environmental
• Legal
• Porter's Five Forces Analysis
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential of New Entrants
• Threat of Substitutes
• Competition in the Industry
• Supply Chain and Logistics for Hematological Instruments
• Market Dynamics of Drugs and Diagnostics for Hematological Disorders
• Market Drivers
• Incidence of Blood Disorders
• Rising Use of Automation
• Diagnosis of Hematology Disorders
• Increasing Government and Private Funding for Treatment
• Market Restraints
• High Cost of Instruments
• High Cost of Treatment
• Reimbursement Challenges for Physicians
• Market Opportunities
• Rising Health Awareness
• Emerging Economies
• Emerging Technologies and Developments
• AI-Assisted Diagnosis
• Next-Generation Sequencing (NGS)
• Microfluidics and Lab-on-a-Chip Devices
• Gene Therapies
• Immunotherapies
• Market Segmentation Analysis
• Segmentation by Market
• Hematological Disorders Diagnostics Market
• Hematological Disorders Diagnostic Market, By Product Type
• Hematological Disorders Diagnostic Market, By End User
• Hematology Drug Market
• Hematology Drug Market, By Drug Type
• Geographic Breakdown
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 5 In Vitro Diagnostics (IVD) Quality Controls: Global Market( BIO233B)

• In Vitro Diagnostics (IVD) Quality Controls
• Market Outlook
• Scope of Report
• Market Summary
• Market and Technology Background
• Overview
• Classification of In Vitro Diagnostics Elements
• Importance of In Vitro Diagnostics Quality Control
• Regulations
• Regulation of IVD products in Different countries
• Market Dynamics of In Vitro Diagnostics (IVD) Quality Controls
• Market Drivers
• Rise in the Aging Population and Dependency on Frequent Diagnosis Procedures
• Rising Demand for Third-Party Quality Control Products
• Rising Incidence of Chronic Disease Cases
• Strengthening Clinical Laboratories
• Improving the Quality of Point-of-Care Testing
• Market Restraints
• Challenges for Quality Control Product Packaging
• Increases in Shipping Costs or Service Issues
• Improper Operation and Maintenance of Laboratory Equipment and Consumables
• Market Opportunities
• Rise in Home Care Testing Devices
• Demand for Point-of-Care (POC) Testing Units
• Emerging Technologies and Developments
• Artificial Intelligence
• Prioritizing Old IVD Techniques
• Automating In-Vitro Diagnostic Devices
• Emerging Trends in In Vitro Diagnostics
• FDA Approval
• Rise in Demand for Personalized Medicine
• Market Segmentation Analysis
• Market Breakdown of In Vitro Diagnostics (IVD) Quality Controls by Test Type
• Immunodiagnostics
• Clinical Chemistry
• Hematology
• Molecular Diagnostics
• Microbiology
• Other Test Types
• Market Breakdown of In Vitro Diagnostics (IVD) Quality Controls by Type of Manufacturer
• Third-party Controls
• ODM Controls
• Market Breakdown of In Vitro Diagnostics (IVD) Quality Controls by Products and Services
• Quality Control Products
• Data Management Solutions
• Quality Assurance Services
• Market Breakdown of In Vitro Diagnostics (IVD) Quality Controls by End User
• Diagnostic Laboratories
• Hospitals and Clinics
• Point-of-Care Centers
• Research Institutions
• Other End Users
• Geographic Breakdown
• Market Analysis of In Vitro Diagnostics (IVD) Quality Controls by Region
• North America
• Market Size and Forecast
• U.S.
• Canada
• Mexico
• Europe
• Market Size and Forecast
• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Market Size and Forecast
• Japan
• China
• India
• Australia and New Zealand
• Rest of Asia-Pacific
• Rest of the World
• Market Size and Forecast
• Brazil
• GCC Countries
• Rest of the World Countries

Chapter 6 Point-of-Care Diagnostics: Technologies and Global Markets ( HLC043H)

• Point-of-Care Diagnostics
• Market Outlook
• Scope of Report
• Market Summary
• Market Overview of Point-of-Care Diagnostics
• Novel Approaches for POC
• Significance of CLIA in the United States
• Regulatory Guidelines
• Good Manufacturing Practice
• The FDA's Role in POC Testing
• Conclusion
• Market Dynamics of Point-of-Care Diagnostics
• Market Drivers
• High Incidences of Infectious Diseases
• Growing Prevalence of Chronic Diseases
• Increasing Demand for Self-Testing
• Aging Population
• Market Restraints
• Challenges Faced by POC Manufacturers Due to Pricing Pressure
• Technical Complexity
• Lack of Specialized Training
• Market Challenges
• Challenges in Deploying Point-of-Care (POC) Diagnostics in Remote Settings
• Environmental and Contamination Challenges in Point-of-Care Diagnostics
• Market Opportunities
• Increasing R&D Budget
• Excellent Market Potential for POCT with AI and ML Integration
• Emerging Economies
• Emerging and Upcoming Technologies in the Market
• AI in Point-of-Care Diagnostics
• CRISPR-Cas Systems
• 3D Rapid Prototyping
• Quantum Dots
• RFID (Radio-Frequency Identification) and NFC (Near Field Communication)
• Smartphone-Based Medical Imaging
• Nanomaterials in POC Devices for Pathogen Detection
• Microfluidics-Based Sensing Technologies
• Cloud-Integrated AI
• D3 Array-UTI
• EVIK DxSpheres: A Solid Assay Solution
• UNIQO 160 Automated IIFT System
• Recent Developments
• Market Segmentation Analysis
• Market Breakdown of Point-of-Care Diagnostics by Test Type
• Drug and Alcohol Screening
• Blood Gas Electrolyte and Metabolite (BGEM)
• Cardiac Markers
• Cholesterol Testing/Monitoring
• Glucose Testing and Monitoring
• Infectious Disease Testing
• Pregnancy and Fertility Testing
• Hemoglobin and Hemostasis
• Tumor Marker
• Urinalysis/Urine Chemistry
• Others
• Market Breakdown of Point-of-Care Diagnostics Market by Product
• Hardware
• Software
• Market Breakdown of Point-of-Care Diagnostics Market by End User
• Hospitals and Critical Care Settings
• Home Care Settings
• Geographic Breakdown
• Market Breakdown of Point-of-Care Diagnostics Market by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Chapter 7 Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics (BIO157C)

• Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics
• Market Outlook
• Scope of Report
• Market Summary
• Market Overview of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics
• Polymerase Chain Reaction Technology
• Point of Care PCR Systems and Assays
• Market Dynamics of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics
• Market Drivers
• Increasing Incidence of Infectious Diseases
• Decentralization of Testing
• Increasing Adoption of Point-of-Care Testing and Expansion
• Multiplexing Testing
• Response to the Pandemics
• Market Opportunities
• Integration of PCR POC Technology in Primary Care and Low-Income Countries
• Market Restraints
• High Initial Cost
• Market Competition
• Market Challenges
• Operational Challenges
• Supply Shortages
• Emerging Technologies and Developments
• Instrument-Free PCR Tests
• Five-Minute Point-of-Care Testing
• Smartphone Enabled PCR System
• Global Market for PCR POC Diagnostics
• Market Breakdown of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics by Product Type
• Market Breakdown of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics by Analyte
• PCR POC Analyzers by Analyte
• PCR POC Consumables by Analyte
• Market Breakdown of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics by Application
• Infectious Diseases
• STIs
• Geographic Breakdown
• Market Breakdown of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics by Region
• North America
• Latin America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 8 Rare Disease Diagnostics: Technologies and Global Markets (PHM227B)

• Rare Disease Diagnostics
• Market Outlook
• Scope of Report
• Market Summary
• Market Overview of Rare Disease Diagnostics
• Diagnostic Odyssey
• What Is Genomic Testing?
• Rare Disease Clinical Assays Development and Marketing
• Rare Disease Treatment
• Bioinformatic Resources for Rare Disease Research and Genetic Information
• Large-Scale Initiatives and Consortia
• Population Sequencing Programs
• Market Dynamics of Rare Disease Diagnostics
• Market Drivers
• Significant Unmet Need in Rare Disease Diagnostics
• Orphan Drug Act
• Advances In Gene Therapy
• Rare Disease Initiatives
• Advances in Genomic Technologies and Analytical Tools
• Decreasing Cost of Next-Generation Sequencing (NGS)
• Market Driving Forces and Their Impact on Market Growth
• Market Restraints
• Lack of Commercially Available IVDs for Rare Disease Diagnosis
• Stringent Regulatory Landscape
• Ethical and Legal Concerns
• Shortage of Genetic and Rare Disease Specialists
• Emerging Technologies and Developments
• Shift Towards a Multi-omics Approach
• Artificial Intelligence (AI) and Machine Learning
• Collaboration Between Rare Disease Diagnostics and Pharma Companies
• Market Segmentation Analysis
• Market Breakdown of Rare Disease Diagnostics by Analysis Platform
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Sanger Sequencing
• Microarrays
• Karyotyping and Fluorescent in Situ Hybridization (FISH)
• Biochemical Testing
• Market Breakdown of Rare Disease Diagnostics by Analysis Target Type
• Single Genes
• Multiple Genes
• Whole Exome
• Whole Genome
• Other Genomic Variants
• Protein and Other Biochemical Markers
• Market Breakdown of Rare Disease Diagnostics by Disease Class
• Rare Cancers
• Neurological Diseases
• Metabolic and Endocrine Disorders
• Hematology
• Respiratory
• Immune System and Inflammation-Related Disorders
• Dermatology
• Musculoskeletal
• Others
• Market Breakdown of Rare Disease Diagnostics by Test Purpose
• Diagnosis
• Screening and Early Detection
• Therapy Guidance
• Monitoring
• Geographic Breakdown
• Market Breakdown of Rare Disease Diagnostics by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 9 Appendix

• Methodology
• Analyst's Credentials

List of Tables

• Table 1 : Global Market for AI in Clinical and Molecular Diagnostics, by Type, Through 2029
• Table 2 : Global Market for AI in Clinical and Molecular Diagnostics, by Region, Through 2029
• Table 3 : Regulations Pertaining to AI Medical Diagnostics
• Table 4 : Global Market for AI in Clinical and Molecular Diagnostics, Through 2029
• Table 5 : Global Market for AI in Clinical and Molecular Diagnostics, by Type, Through 2029
• Table 6 : Global Market for AI in Molecular Diagnostics, by Application, Through 2029
• Table 7 : Incidence of Cancer, by Region, 2022
• Table 8 : Number of DALYs for Neurological Disorders and Share of Global DALYs Projected for 2005 and 2030
• Table 9 : Global Market for AI in Molecular Diagnostics, by Product Type, Through 2029
• Table 10 : Global Market for AI in Clinical Diagnostics, by Test, Through 2029
• Table 11 : Global Market for AI in Clinical Diagnostics, by Product, Through 2029
• Table 12 : Global Market for AI in Clinical and Molecular Diagnostics, by Component, Through 2029
• Table 13 : Global Market for AI in Clinical and Molecular Diagnostics, by Region, Through 2029
• Table 14 : North American Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029
• Table 15 : European Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029
• Table 16 : Asia-Pacific Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029
• Table 17 : RoW Market for AI in Clinical and Molecular Diagnostics, by Sub-Region, Through 2029
• Table 18 : Global Market for Companion Diagnostics, by Product, Through 2028
• Table 19 : Global Market for Companion Diagnostics, by Region, Through 2028
• Table 20 : Expanded/New CDx Testing for Personalized Medicine in 2022
• Table 21 : Global Market for Companion Diagnostics, by Product and Service, Through 2028
• Table 22 : Companion Diagnostics Instruments
• Table 23 : Global Market for Companion Diagnostics Instruments, by Region, Through 2028
• Table 24 : Global Market for Companion Diagnostics Consumables, by Region, Through 2028
• Table 25 : Global Market for Companion Diagnostics Services, by Region, Through 2028
• Table 26 : Global Market for Companion Diagnostics, by Type of Test, Through 2028
• Table 27 : Global Market for Laboratory Developed Test (LDT)-CDx, by Region, Through 2028
• Table 28 : List of FDA-Approved Companion Diagnostics, by Company, as of December 2023
• Table 29 : Global Market for Commercial-CDx, by Region, Through 2028
• Table 30 : FDA-Approved CDx Tests, by Technology, as of December 2023
• Table 31 : Global Market for Companion Diagnostics, by Technology, Through 2028
• Table 32 : List of FDA-Approved PCR-CDx, by Company, as of December 2023
• Table 33 : Global Market for Polymerase Chain Reaction CDx, by Region, Through 2028
• Table 34 : Global Market for Polymerase Chain Reaction CDx, by Application, Through 2028
• Table 35 : List of FDA-Approved IHC-CDx, by Company, as of December 2023
• Table 36 : Global Market for Immunohistochemistry CDx, by Region, Through 2028
• Table 37 : Global Market for Immunohistochemistry CDx, by Application, Through 2028
• Table 38 : List of FDA-Approved NGS-CDx, by Company, as of December 2023
• Table 39 : Global Market for Next-Generation Sequencing CDx, by Region, Through 2028
• Table 40 : Global Market for Next-Generation Sequencing CDx, by Application, Through 2028
• Table 41 : Global Market for In Situ Hybridization CDx, by Region, Through 2028
• Table 42 : Global Market for In Situ Hybridization CDx, by Application, Through 2028
• Table 43 : Global Market for Genotyping CDx, by Region, Through 2028
• Table 44 : Global Market for Genotyping CDx, by Application, Through 2028
• Table 45 : Global Market for Immunoassays CDx, by Region, Through 2028
• Table 46 : Global Market for Immunoassays CDx, by Application, Through 2028
• Table 47 : Global Market for Exosome CDx, by Region, Through 2028
• Table 48 : Global Market for Exosomes CDx, by Application, Through 2028
• Table 49 : Global Market for Other CDx, by Region, Through 2028
• Table 50 : Global Market for Other CDx, by Application, Through 2028
• Table 51 : Technological Expertise in the CDx Services Sector
• Table 52 : Global Market for CDx Services, by Region, Through 2028
• Table 53 : Global Market for CDx Services, by Application, Through 2028
• Table 54 : Global Market for Companion Diagnostics, by Application, Through 2028
• Table 55 : Global Market for Companion Diagnostics in Cancer Applications, by Region, Through 2028
• Table 56 : Cancer Incidence, Global, by Cancer Type, 2022
• Table 57 : Approved CDx Drugs for Cancer Treatment, by Cancer Type, 2023
• Table 58 : Global Market for Companion Diagnostics in Cancer Applications, by Cancer Type, Through 2028
• Table 59 : Global Market for Companion Diagnostics in Neurologic Disorder Applications, by Region, Through 2028
• Table 60 : Global Market for Companion Diagnostics in Neurologic Disorder Applications, by Type, Through 2028
• Table 61 : Global Market for Companion Diagnostics in Cardiovascular Disease Applications, by Region, Through 2028
• Table 62 : Global Market for Companion Diagnostics in Infectious Disease Applications, by Region, Through 2028
• Table 63 : Global Market for Companion Diagnostics in Other Disease Applications, by Region, Through 2028
• Table 64 : Global Market for Companion Diagnostics, by End User, Through 2028
• Table 65 : Global Market for Companion Diagnostics in Clinical Laboratories, by Region, Through 2028
• Table 66 : Recent Collaborations and Partnerships in the Companion Diagnostics Market, 2022 and 2023
• Table 67 : Global Market for Companion Diagnostics in Pharmaceutical Companies, by Region, Through 2028
• Table 68 : Global Market for Companion Diagnostics in Contract Research Organizations, by Region, Through 2028
• Table 69 : Global Market for Companion Diagnostics in Other End Users, by Region, Through 2028
• Table 70 : Global Market for Companion Diagnostics, by Region, Through 2028
• Table 71 : North American Market for Companion Diagnostics, by Country, Through 2028
• Table 72 : European Market for Companion Diagnostics, by Country, Through 2028
• Table 73 : Asia-Pacific Market for Companion Diagnostics, by Country, Through 2028
• Table 74 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029
• Table 75 : Blood-Related Disorders
• Table 76 : Incidence of Blood Cancer Types in U.S., 2023
• Table 77 : Total Cost of Care for CLL Patients Treated in the U.S., 2023
• Table 78 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
• Table 79 : Global Market for Diagnostics for Hematological Disorders, by Region, Through 2029
• Table 80 : Global Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
• Table 81 : Global Market for Hematology Instruments and Software, by Region, Through 2029
• Table 82 : Global Market for Hematology Reagents, by Region, Through 2029
• Table 83 : Global Market for Diagnostics for Hematological Disorders, by End User, Through 2029
• Table 84 : Global Market for Hematology Diagnosis in Diagnostic Centers, by Region, Through 2029
• Table 85 : Global Market for Hematology Diagnosis in Hospitals and Clinics, by Region, Through 2029
• Table 86 : Global Market for Hematology Diagnosis in Other End Users, by Region, Through 2029
• Table 87 : Global Market for Hematology Drugs, by Region, Through 2029
• Table 88 : Global Market for Hematology Drugs, by Drug Type, Through 2029
• Table 89 : Drugs Approved for Hematologic Cancers
• Table 90 : Global Market for Hematology Oncology Drugs, by Region, Through 2029
• Table 91 : Global Market for Hematology Non-Oncology Drugs, by Region, Through 2029
• Table 92 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029
• Table 93 : North American Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
• Table 94 : North American Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
• Table 95 : North American Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
• Table 96 : North American Market for Diagnostics for Hematological Disorders, by End User, Through 2029
• Table 97 : North American Market for Hematology Drugs, by Drug Type, Through 2029
• Table 98 : European Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
• Table 99 : European Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
• Table 100 : European Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
• Table 101 : European Market for Diagnostics for Hematological Disorders, by End User, Through 2029
• Table 102 : European Market for Hematology Drugs, by Drug Type, Through 2029
• Table 103 : Incidence of Blood-Related Cancers, by Country, 2022
• Table 104 : Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
• Table 105 : Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
• Table 106 : Asia-Pacific Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
• Table 107 : Asia-Pacific Market for Diagnostics for Hematological Disorders, by End User, Through 2029
• Table 108 : Asia-Pacific Market for Hematology Drugs, by Drug Type, Through 2029
• Table 109 : Asia-Pacific Incidence of Blood-Related Cancers, by Country, 2022
• Table 110 : RoW Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
• Table 111 : RoW Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
• Table 112 : RoW Market for Diagnostics for Hematological Disorders, by End User, Through 2029
• Table 113 : RoW Market for Hematology Drugs, by Drug Type, Through 2029
• Table 114 : Global Market for In Vitro Diagnostics Quality Controls, by Test Type, Through 2029
• Table 115 : Global Market for In Vitro Diagnostics Quality Controls, by Test Type, Through 2029
• Table 116 : Global Market for Immunodiagnostics, by Region, Through 2029
• Table 117 : Global Market for Clinical Chemistry, by Region, Through 2029
• Table 118 : Global Market for Hematology, by Region, Through 2029
• Table 119 : Global Market for Molecular Diagnostics, by Region, Through 2029
• Table 120 : Global Market for Microbiology, by Region, Through 2029
• Table 121 : Global Market for Other Test Types, by Region, Through 2029
• Table 122 : Global Market for In Vitro Diagnostics Quality Controls, by Type of Manufacturer, Through 2029
• Table 123 : Global Market for Third-party Controls, by Region, Through 2029
• Table 124 : Global Market for ODM Controls, by Region, Through 2029
• Table 125 : Global Market for In Vitro Diagnostics Quality Controls, by Type of Product and Service, Through 2029
• Table 126 : Global Market for Quality Control Products, by Region, Through 2029
• Table 127 : Global Market for Serum/Plasma-Based Controls, by Region, Through 2029
• Table 128 : Global Market for Whole Blood-Based Controls, by Region, Through 2029
• Table 129 : Global Market for Urine-based Controls, by Region, Through 2029
• Table 130 : Global Market for Other Quality Control Products, by Region, Through 2029
• Table 131 : Global Market for Data Management Solutions, by Region, Through 2029
• Table 132 : Global Market for Quality Assurance Services, by Region, Through 2029
• Table 133 : Global Market for In Vitro Diagnostics Quality Controls, by End User, Through 2029
• Table 134 : Global Market for IVD Quality Controls in Diagnostic Laboratories, by Region, Through 2029
• Table 135 : Global Market for IVD Quality Controls in Hospitals and Clinics, by Region, Through 2029
• Table 136 : Global Market for IVD Quality Controls in Point-of-Care Centers, by Region, Through 2029
• Table 137 : Global Market for IVD Quality Controls in Research Institutions, by Region, Through 2029
• Table 138 : Global Market for Other End Users, by Region, Through 2029
• Table 139 : Global Market for In Vitro Diagnostics Quality Controls, by Region, Through 2029
• Table 140 : North American Market for In Vitro Diagnostics Quality Controls, by Country, Through 2029
• Table 141 : European Market for In Vitro Diagnostics Quality Controls, by Country, Through 2029
• Table 142 : Asia-Pacific Market for In Vitro Diagnostics Quality Controls, by Country, Through 2029
• Table 143 : Rest of the World Market for In Vitro Diagnostics Quality Controls, by Country/Sub-Region, Through 2029
• Table 144 : Global Market for Point-of-Care Diagnostics, by Region, Through 2029
• Table 145 : POCT Alternatative Terms
• Table 146 : Commonly Used POC Devices
• Table 147 : Recent Tests Approved by the FDA as Waived Tests Under CLIA
• Table 148 : Estimated Number of People Living with HIV, 2010, 2021 and 2022
• Table 149 : Number of Hepatitis B Infections (All Ages) in 2022
• Table 150 : Global Incidences of STIs, 2020 and 2022
• Table 151 : Projected Number of Adults 50 Years and Older with >=1 Chronic Condition in the United States, 2020-2050
• Table 152 : Number and Proportion of Persons Aged 65 Years and Over, by Development Group, 2023 and 2050
• Table 153 : Number of Persons Aged 65 Years and Over, by Region, 2019 and 2050
• Table 154 : Number of Deaths and the Age-Adjusted Death Rate for the 10 Leading Causes of Death in 2022: United States, 2021 and 2022
• Table 155 : Global Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 156 : Global Market for Drug and Alcohol Screening, by Region, Through 2029
• Table 157 : Global Market for BGEM, by Region, Through 2029
• Table 158 : Global Market for Cardiac Markers, by Region, Through 2029
• Table 159 : Global Market for Cholesterol Testing/Monitoring, by Region, Through 2029
• Table 160 : Global Market for Glucose Testing and Monitoring, by Region, Through 2029
• Table 161 : Annual Estimated Deaths from HIV/AIDS, Diarrhea, Malaria, Respiratory Infections, and All Other Infectious Diseases in Major Countries, 1980 to 2021
• Table 162 : Global Market for Infectious Disease Testing, by Region, Through 2029
• Table 163 : Global Market for Pregnancy and Fertility Testing, by Region, Through 2029
• Table 164 : Global Market for Hemoglobin and Hemostasis, by Region, Through 2029
• Table 165 : Examples of Commercially Available POC Devices for Cancer Detection
• Table 166 : Global Market for Tumor Markers, by Region, Through 2029
• Table 167 : Some Currently Available Point-of-Care Tests for Proteins in Urine
• Table 168 : Global Market for Urinalysis/Urine Chemistry, by Region, Through 2029
• Table 169 : Global Market for Other Types of Point-of-Care Diagnostics Tests, by Region, Through 2029
• Table 170 : Global Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 171 : Global Market for Hardware in Point-of-Care Diagnostics, by Region, Through 2029
• Table 172 : Global Market for Software in Point-of-Care Diagnostics, by Region, Through 2029
• Table 173 : Global Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 174 : Global Market for Point-of-Care Diagnostics in Hospital and Critical Care End Uses, by Region, Through 2029
• Table 175 : Global Market for Point-of-Care Diagnostics in Home Care Settings, by Region, Through 2029
• Table 176 : Global Market for Point-of-Care Diagnostics, by Region, Through 2029
• Table 177 : North American Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 178 : North American Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 179 : North American Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 180 : North American Market for Point-of-Care Diagnostics, by Country, Through 2029
• Table 181 : U.S. Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 182 : U.S. Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 183 : U.S. Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 184 : Canadian Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 185 : Canadian Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 186 : Canadian Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 187 : Mexican Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 188 : Mexican Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 189 : Mexican Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 190 : European Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 191 : European Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 192 : European Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 193 : European Market for Point-of-Care Diagnostics, by Country, Through 2029
• Table 194 : Leading Causes of Disease Burden by DALYs (Level 3)
• Table 195 : German Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 196 : German Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 197 : German Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 198 : U.K. Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 199 : U.K. Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 200 : U.K. Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 201 : French Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 202 : French Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 203 : French Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 204 : Italian Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 205 : Italian Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 206 : Italian Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 207 : Spanish Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 208 : Spanish Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 209 : Spanish Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 210 : Rest of European Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 211 : Rest of European Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 212 : Rest of European Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 213 : Asia-Pacific Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 214 : Asia-Pacific Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 215 : Asia-Pacific Market for Point-of-Care Diagnostics, by End User Through 2029
• Table 216 : Asia-Pacific Market for Point-of-Care Diagnostics, by Country, Through 2029
• Table 217 : Chinese Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 218 : Chinese Market for Point-of-Care Diagnostics, by Product, Through 2029Chinese Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 219 : Chinese Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 220 : Japanese Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 221 : Japanese Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 222 : Japanese Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 223 : Indian Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 224 : Indian Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 225 : Indian Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 226 : Australian Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 227 : Australian Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 228 : Australian Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 229 : South Korean Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 230 : South Korean Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 231 : South Korean Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 232 : Rest of Asia-Pacific Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 233 : Rest of Asia-Pacific Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 234 : Rest of Asia-Pacific Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 235 : Rest of the World Market for Point-of-Care Diagnostics, by Test Type, Through 2029
• Table 236 : Rest of the World Market for Point-of-Care Diagnostics, by Product, Through 2029
• Table 237 : Rest of the World Market for Point-of-Care Diagnostics, by End User, Through 2029
• Table 238 : Global Market for Polymerase Chain Reaction for Point-of-Care Diagnostics, by Product Type, Through 2029
• Table 239 : Global HIV Infections, 2022
• Table 240 : People Living with HIV, by Region, 2022
• Table 241 : Global Incidence of All Cancers, by Region, 2022-2050
• Table 242 : Global Incidence of Leukemia, by Region, 2022-2050
• Table 243 : Global Incidence of Hodgkin Lymphoma, by Region, 2022-2050
• Table 244 : Global Incidence of Non-Hodgkin Lymphoma, by Region, 2022-2050
• Table 245 : Global Incidence of Multiple Myeloma, by Region, 2022-2050
• Table 246 : Global Market for PCR POC Diagnostics, Through 2029
• Table 247 : Global Market for PCR POC Diagnostics, by Product Type, Through 2029
• Table 248 : Global Market for PCR POC Analyzers, by Analyte, Through 2029
• Table 249 : Global Market for Single Analyte PCR POC Analyzers, by Region, Through 2029
• Table 250 : Global Market for Multi-Analyte PCR POC Analyzers, by Region, Through 2029
• Table 251 : Global Market for PCR POC Consumables, by Analyte, Through 2029
• Table 252 : Global Market for Single Analyte PCR POC Consumables, by Region, Through 2029
• Table 253 : Global Market for Multi-Analyte PCR POC Consumables, by Region, Through 2029
• Table 254 : Global Market for PCR for POC Diagnostics, by Application, Through 2029
• Table 255 : Global Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
• Table 256 : Global Market for PCR POC Diagnostics in Infectious Diseases, by Region, Through 2029
• Table 257 : North American Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
• Table 258 : North American Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029
• Table 259 : Latin American Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
• Table 260 : Latin American Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029
• Table 261 : European Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
• Table 262 : European Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029
• Table 263 : Asia-Pacific Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
• Table 264 : Asia-Pacific Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029
• Table 265 : RoW Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
• Table 266 : Global Market for PCR POC Diagnostics in STIs, Through 2029
• Table 267 : Global Market for PCR POC Diagnostics in STIs, by Region, Through 2029
• Table 268 : North American Market for PCR POC Diagnostics in STIs, Through 2029
• Table 269 : North American Market for PCR POC Diagnostics in STIs, by Country, Through 2029
• Table 270 : Latin American Market for PCR POC Diagnostics in STIs, Through 2029
• Table 271 : Latin American Market for PCR POC Diagnostics in STIs, by Country, Through 2029
• Table 272 : European Market for PCR POC Diagnostics in STIs, Through 2029
• Table 273 : European Market for PCR POC Diagnostics in STIs, by Country, Through 2029
• Table 274 : Asia-Pacific Market for PCR POC Diagnostics in STIs, Through 2029
• Table 275 : Asia-Pacific Market for PCR POC Diagnostics in STIs, by Country, Through 2029
• Table 276 : RoW Market for PCR POC Diagnostics in STIs, Through 2029
• Table 277 : Global Market for PCR for POC Diagnostics, by Region, Through 2029
• Table 278 : North American Market for PCR POC Diagnostics, by Product Type, Through 2029
• Table 279 : North American Market for PCR POC Diagnostics, by Country, Through 2029
• Table 280 : Latin American Market for PCR POC Diagnostics, by Product Type, Through 2029
• Table 281 : Latin American Market for PCR POC Diagnostics, by Country, Through 2029
• Table 282 : European Market for PCR POC Diagnostics, by Product Type, Through 2029
• Table 283 : European Market for PCR POC Diagnostics, by Country, Through 2029
• Table 284 : Asia-Pacific Market for PCR POC Diagnostics, by Product Type, Through 2029
• Table 285 : Asia-Pacific Market for PCR POC Diagnostics, by Country, Through 2029
• Table 286 : RoW Market for PCR POC Diagnostics, by Product Type, Through 2029
• Table 287 : Global Market for Rare Disease Diagnostics, by Disease Class, Through 2029
• Table 288 : Rare Disease Prevalence Definitions
• Table 289 : Statistics for Rare Diseases
• Table 290 : Most Prevalent Rare Diseases
• Table 291 : Examples of Genomic Biomarkers
• Table 292 : Rare Disease Diagnostics Key Genetic Analysis Platforms
• Table 293 : Genome Coverage of PCR, Microarray and NGS Technology Platforms
• Table 294 : NGS vs. qPCR vs. Microarrays: A Detailed Comparison
• Table 295 : Multiple Paths to Market for Rare Disease Tests
• Table 296 : Bioinformatic Resources for Rare Disease Research and Genetic Information
• Table 297 : Impact of Large-Scale Initiatives on the Rare Disease Diagnostic Industry
• Table 298 : Key Rare Disease Initiatives
• Table 299 : Population Sequencing Projects
• Table 300 : Pathways for Accelerated Approval of Rare Disease Therapies, by Country/Region
• Table 301 : Genetic Modification Approaches for Rare Diseases
• Table 302 : Distinct Features of the Genetic Modification Approaches
• Table 303 : Comparison of Clinical Genomic Testing Methods for Analysis of Genomic Variants
• Table 304 : Driving Forces and Their Impact on Rare Disease Diagnostic Market Growth
• Table 305 : Rare Disease Diagnostics Artificial Intelligence Industry
• Table 306 : Global Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 307 : NGS Applications in Rare Diseases
• Table 308 : Key Forces Driving Growth in Clinical NGS and Their Implications
• Table 309 : Main Ingredients for Polymerase Chain Reaction
• Table 310 : Polymerase Chain Reaction Process Steps
• Table 311 : Sanger Sequencing Summary
• Table 312 : Sanger Sequencing Improvements
• Table 313 : Molecular Genetic Testing Methods
• Table 314 : Cytogenetics Testing Methods
• Table 315 : Biochemical Genetics Methods
• Table 316 : Global Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
• Table 317 : Single-Gene Disorders
• Table 318 : Comparison of Techniques Employed to Study Rare Genetic Diseases
• Table 319 : Comparison of Genomic Methods for Rare Disease Diagnosis
• Table 320 : Global Market for Rare Disease Diagnostics, by Disease Class, Through 2029
• Table 321 : Rare Cancer-Focused Initiatives and Consortia
• Table 322 : Selected Rare Cancer Prevalence, 2022
• Table 323 : Global Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 324 : Preventive Genetic Screening Tests
• Table 325 : Global Market for Rare Disease Diagnostics, by Region, Through 2029
• Table 326 : NIH Funding, 2018-FY2025
• Table 327 : Key FDA Programs to Support Rare Disease Research
• Table 328 : North American Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 329 : North American Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
• Table 330 : North American Market for Rare Disease Diagnostics, by Disease Class, Through 2029
• Table 331 : North American Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 332 : North American Market for Rare Disease Diagnostics, by Country, Through 2029
• Table 333 : U.S. Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 334 : U.S. Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 335 : Canadian Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 336 : Canadian Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 337 : Mexican Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 338 : Mexican Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 339 : Overview of Actions Taken by the EU to Address Challenges in the Field of Rare Diseases Diagnosis
• Table 340 : European Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 341 : European Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
• Table 342 : European Market for Rare Disease Diagnostics, by Disease Class, Through 2029
• Table 343 : European Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 344 : European Market for Rare Disease Diagnostics, by Country, Through 2029
• Table 345 : German Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 346 : German Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 347 : U.K. Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 348 : U.K. Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 349 : French Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 350 : French Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 351 : Italian Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 352 : Italian Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 353 : Spanish Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 354 : Spanish Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 355 : Rest of European Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 356 : Rest of European Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 357 : Asia-Pacific Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 358 : Asia-Pacific Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
• Table 359 : Asia-Pacific Market for Rare Disease Diagnostics, by Disease Class, Through 2029
• Table 360 : Asia-Pacific Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 361 : Asia-Pacific Market for Rare Disease Diagnostics, by Country, Through 2029
• Table 362 : Chinese Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 363 : Chinese Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 364 : Japanese Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 365 : Japanese Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 366 : Australian Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 367 : Australian Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 368 : South Korean Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 369 : South Korean Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 370 : Rest of Asia-Pacific Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 371 : Rest of Asia-Pacific Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
• Table 372 : RoW Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
• Table 373 : RoW Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
• Table 374 : RoW Market for Rare Disease Diagnostics, by Disease Class, Through 2029
• Table 375 : RoW Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

List of Figures

• Figure 1 : Market Dynamics of AI in Clinical and Molecular Diagnostics
• Figure 2 : Global Market Shares of AI in Clinical and Molecular Diagnostics, by Type, 2023
• Figure 3 : Global Market Shares of AI in Molecular Diagnostics, by Application, 2023
• Figure 4 : Global Deaths from Cancer, 2015 and 2030
• Figure 5 : Global Market Shares of AI in Molecular Diagnostics, by Product Type, 2023
• Figure 6 : Global Market Shares of AI in Clinical Diagnostics, by Test, 2023
• Figure 7 : Global Market Shares of AI in Clinical Diagnostics, by Product, 2023
• Figure 8 : Global Market Shares of AI in Clinical and Molecular Diagnostics, by Component, 2023
• Figure 9 : Global Market Shares of AI in Clinical and Molecular Diagnostics, by Region, 2023
• Figure 10 : North American Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023
• Figure 11 : European Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023
• Figure 12 : Asia-Pacific Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023
• Figure 13 : RoW Market Shares of AI in Clinical and Molecular Diagnostics, by Sub-Region, 2023
• Figure 14 : Timeline of FDA Guidance Release for Companion Diagnostics (CDx), as of 2023
• Figure 15 : Market Dynamics of Companion Diagnostics
• Figure 16 : Share of Global Cancer Incidence for Both Sexes, by Region, 2022
• Figure 17 : Companion Diagnostics: Growing Share in Total New Molecular Entities (NMEs), 2019-2022
• Figure 18 : Emerging Trends/Technologies in the Companion Diagnostics Market
• Figure 19 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, 2021-2029
• Figure 20 : Market Dynamics of Drugs and Diagnostics for Hematological Disorders
• Figure 21 : Incidence of Blood Cancer Types, by Region, 2022
• Figure 22 : Global Market Shares of Drugs and Diagnostics for Hematological Disorders, by Segment, 2023
• Figure 23 : Global Market Shares of Diagnostics for Hematological Disorders, by Product Type, 2023
• Figure 24 : Global Market Shares of Diagnostics for Hematological Disorders, by End User, 2023
• Figure 25 : Global Market Shares of Hematology Drugs, by Drug Type, 2023
• Figure 26 : North American Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
• Figure 27 : New Cases of Leukemia, Lymphoma and Myeloma in U.S., 2023
• Figure 28 : European Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
• Figure 29 : Asia-Pacific Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
• Figure 30 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
• Figure 31 : In Vitro Diagnostics (IVD) Quality Controls Global Market: Market Dynamics
• Figure 32 : Distribution of Elderly Population (Aged 65 and above), by Top Countries, 2022
• Figure 33 : Comparison Between Third-Party Controls and Original Equipment Manufacturer Controls
• Figure 34 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Test Type 2023
• Figure 35 : Global Market Shares of In Vitro Diagnostics Quality Control, by Type of Manufacturer 2023
• Figure 36 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Type of Product and Service, 2023
• Figure 37 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Type of Quality Control Product, 2023
• Figure 38 : Global Market Shares of In Vitro Diagnostics Quality Controls, by End-user, 2023
• Figure 39 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Region, 2023
• Figure 40 : North American Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
• Figure 41 : North American Market Shares of In Vitro Diagnostics Quality Controls, by Type of Manufacturer, 2023
• Figure 42 : North American Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023
• Figure 43 : North American Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023
• Figure 44 : North American Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023
• Figure 45 : North American Market Shares of In Vitro Diagnostics Quality Controls, by Country, 2023
• Figure 46 : European Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
• Figure 47 : European Market Shares of In Vitro Diagnostics Quality Controls, by Type of Manufacturer, 2023
• Figure 48 : European Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023
• Figure 49 : European Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023
• Figure 50 : European Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023
• Figure 51 : European Market Shares of In Vitro Diagnostics Quality Controls, by Country, 2023
• Figure 52 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
• Figure 53 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Type of Manufacturer, 2023
• Figure 54 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023
• Figure 55 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023
• Figure 56 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023
• Figure 57 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Country, 2023
• Figure 58 : Rest of World Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
• Figure 59 : Rest of World Market Shares of In Vitro Diagnostic Quality Controls, by Type of Manufacturer, 2023
• Figure 60 : Rest of World Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023
• Figure 61 : Rest of World Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023
• Figure 62 : Rest of World Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023
• Figure 63 : Rest of the World Market Shares of In Vitro Diagnostics Quality Controls, by Country/Sub-Region, 2023
• Figure 64 : Global Market Dynamics of Point-of-Care Diagnostics
• Figure 65 : Malaria-Endemic Countries, 2022
• Figure 66 : Top 10 Common Chronic Conditions in Adults 65+, U.S., 2024
• Figure 67 : Annual Investment in STI Research Needs of People in Low- and Middle-Income Countries, 2018-2022
• Figure 68 : Global Market Shares of Point-of-Care Diagnostics, by Test Type, 2023
• Figure 69 : Share of New Cancer Cases Globally, by Region, 2022
• Figure 70 : Share of Cancer Mortality Cases Globally, by Region, 2022
• Figure 71 : Global Market Shares of Point-of-Care Diagnostics, by Product, 2023
• Figure 72 : Global Market Shares of Point-of-Care Diagnostics, by End User, 2023
• Figure 73 : COVID-19 Diagnostic Possibilities, Sampling, and Turnaround Time
• Figure 74 : Global Market Shares of Point-of-Care Diagnostics, by Region, 2023
• Figure 75 : North American Market Shares in Point-of-Care Diagnostics, by Country, 2023
• Figure 76 : Limitations of Using POC Devices in India
• Figure 77 : Global Market Shares of Polymerase Chain Reaction for Point-of-Care Diagnostics, by Product Type, 2023
• Figure 78 : Polymerase Chain Reaction for Point of Care Diagnostics: Market Dynamics
• Figure 79 : Emerging Trends and Technologies in PCR for POC Diagnostics
• Figure 80 : Global Market Shares of Rare Disease Diagnostics, by Disease Class, 2023
• Figure 81 : Market Dynamics of Rare Disease Diagnostics
• Figure 82 : FDA Approval for Orphan Drugs, 2020-2023
• Figure 83 : Cost Per Genome, November 2017-May 2022
• Figure 84 : Phase-Out Plan of FDA's Enforcement Discretion Approach
• Figure 85 : Global Market Shares of Rare Disease Diagnostics, by Analysis Platform, 2023
• Figure 86 : Global Market Shares of Rare Disease Diagnostics, by Analysis Target, 2023
• Figure 87 : Global Market Shares of Rare Disease Diagnostics, by Disease Class, 2023
• Figure 88 : Global Market Shares of Rare Disease Diagnostics, by Test Purpose, 2023
• Figure 89 : Global Market for Rare Disease Diagnostics, by Region, 2021-2029
• Figure 90 : Global Market Shares of Rare Disease Diagnostics, by Region, 2023
• Figure 91 : NIH Funding for Rare Diseases, 2018-2025E
• Figure 92 : North American Market Shares of Rare Disease Diagnostics, by Country, 2023
• Figure 93 : European Market Shares of Rare Disease Diagnostics, by Country, 2023
• Figure 94 : Asia-Pacific Market Shares of Rare Disease Diagnostics, by Country, 2023